Tonix Pharmaceuticals Holding Corp. — Q2 2013 Form 10-Q
Business context and period. This development-stage specialty pharmaceutical company is developing CNS treatments, principally TNX-102 SL for fibromyalgia (FM) and post-traumatic stress disorder (PTSD). The filing covers the quarter and six months ended June 30, 2013. The company reported no product revenue and had no commercial products.
Financial position and results
| Metric | Q2 2013 / June 30, 2013 | Comparable period / December 31, 2012 |
|---|---|---|
| Revenue | None | None in Q2 2012 or first half 2012 |
| Operating expenses | $2.086 million for Q2; $4.087 million for first half | $1.851 million for Q2 2012; $3.011 million for first half 2012 |
| Net loss | $2.086 million for Q2; $4.087 million for first half; $0.95 and $1.88 per share, respectively | $3.074 million for Q2 2012; $5.089 million for first half 2012; $1.79 and $3.09 per share |
| Cash and restricted cash | $68,037 cash; $60,312 restricted cash | $1.785 million cash; $60,267 restricted cash at December 31, 2012 |
| Current liabilities / working capital | $2.263 million current liabilities; $2.148 million working-capital deficit | $1.139 million current liabilities at December 31, 2012 |
| Total liabilities / equity | $2.278 million liabilities; $1.964 million stockholders’ deficit | $1.159 million liabilities; $959,000 stockholders’ equity at December 31, 2012 |
| Operating cash flow | Cash used of $2.123 million per cash-flow statement | Cash used of $2.907 million in first half 2012 |
Margins are not meaningful because the company had no revenue. First-half R&D expense rose 37% to $1.685 million, principally due to TNX-102 SL development. The financial statements report first-half G&A expense of $2.402 million, versus $1.786 million in 2012. The company reported $833,895 of first-half stock-based compensation. No material long-term debt is shown; current liabilities included $200,000 of related-party advances.
Changes, financing, and outlook
- Net loss declined year over year, but the comparison was affected by 2012 noncash warrant revaluation and financing costs. Those items contributed $1.177 million and $900,349, respectively, to first-half 2012 results; there were no comparable warrant-liability charges in 2013.
- Cash fell substantially during the first half. Financing included $306,666 from warrant exercises and $200,000 in related-party advances.
- After quarter-end, the company closed an underwritten offering on August 14, 2013: 2.68 million units at $4.25 each, with each unit comprising one common share and one warrant. Net proceeds were approximately $10 million. The underwriters also exercised an over-allotment for warrants to purchase 402,000 shares. The filing says the proceeds were expected to fund operations through at least June 30, 2014, but would not cover all studies required for FDA approval. Shares outstanding were 4,877,490 as of August 14.
- Management planned to initiate a potential Phase 2b FM trial in Q3 2013, file a PTSD IND in Q3, and begin a PTSD proof-of-concept trial in Q4. These were plans, not reported completed milestones. Management expected R&D spending to increase significantly over the next 12–24 months and anticipated continued operating losses.
- The auditor had raised substantial doubt about the company’s ability to continue as a going concern at December 31, 2012. Management cited the subsequent offering as expected to fund requirements through at least June 30, 2014. Further financing would be needed; lack of financing could delay, reduce, or eliminate programs and could dilute shareholders.
Risks, contingencies, and other items
Key risks include clinical efficacy and safety, patient recruitment, regulatory delays or rejection, development costs, competition, and the need for additional capital. TNX-102 SL was generally tolerated in a Phase 1 comparison, with transient tongue numbness reported; this does not establish efficacy or approval prospects. The company disclosed no material legal proceedings. Management concluded disclosure controls were effective as of June 30, 2013. Risk factors were not required to be included in this smaller-reporting-company filing.
Facts investors should verify
- Cash-flow discrepancy: the cash-flow statement reports first-half operating cash use of $2.123 million, while MD&A states $2.224 million. Confirm the correct amount.
- G&A discrepancy: the statements report first-half 2013 G&A of $2.402 million; MD&A gives $2.503 million. Confirm the correct expense and year-over-year comparison.
- Confirm the offering’s net proceeds, post-offering share count and warrant overhang, and whether available capital supports the stated clinical plans.
- Track actual initiation and results of the planned FM and PTSD studies, and any regulatory feedback or changes to timelines.
- Assess the company’s ongoing cash burn, working-capital deficit, related-party financing and going-concern risk.